ARCHIVES
VOL. 10, ISSUE 4 (2025)
Formulation of extended release oral dosage forms of Ashwagandha
Authors
Prakash Kumar, Dr. Vijendranath Trivedi, Priya Bisen
Abstract
Ashwagandha (Withania somnifera) is a
well-established adaptogenic herb used in Ayurveda for stress relief, anxiety
reduction, neuroprotection, and immune enhancement. Despite its therapeutic
potential, clinical translation is limited by its low aqueous solubility, rapid
metabolism, and short plasma half-life, leading to irregular bioavailability in
conventional immediate-release (IR) preparations. The present study focuses on the
formulation and evaluation of an extended-release (ER) oral tablet designed
using a hydrophilic–hydrophobic polymer matrix comprising HPMC K4M and ethyl
cellulose. ER tablets were developed through wet granulation and evaluated for in
vitro dissolution, release kinetics, accelerated stability,
pharmacokinetics, and anti-stress efficacy. In vitro dissolution
indicated controlled release of 98% over 12 hours, following zero-order and
Korsmeyer–Peppas kinetics, contrasting with IR tablets which released 100% in 6
hours. Stability analysis showed minimal degradation after 3 months under ICH
conditions. Pharmacokinetic assessment in Wistar rats revealed lower C_max but
significantly higher AUC and prolonged half-life for ER tablets. Stress-model
studies demonstrated superior cortisol reduction and anxiolytic effects.
Overall, the ER Ashwagandha formulation markedly enhances bioavailability,
ensures steady therapeutic exposure, and improves clinical efficacy, making it
a promising dosage form for chronic stress management.
Pages:121-124
How to cite this article:
Prakash Kumar, Dr. Vijendranath Trivedi, Priya Bisen "Formulation of extended release oral dosage forms of Ashwagandha". International Journal of Research in Pharmacy and
Pharmaceutical Sciences, Vol 10, Issue 4, 2025, Pages 121-124
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.